< Brochure Homepage | Faculty Index | Pathology Homepage


Division of Hematologic Pathology


Email mborowit@jhmi.edu
Phone (410) 614-2889

Michael J. Borowitz, M.D., Ph.D.

Deputy Director for Education
Deputy Director for Clinical Affairs
Director, Division of Hematologic Pathology
Primary Appointment in Pathology; Secondary Appointment in Oncology


My research focuses on defining the complexity of hematologic neoplasms. I am particularly interested in the immunologic aspects of leukemia and lymphoma, and in the relation of phenotypic variability to clinical and biological heterogeneity in these diseases. I employ routine morphologic techniques and immunocytochemistry in my investigations, but I am particularly interested in flow cytometry. A major focus of my efforts has been in childhood acute lymphocytic leukemia, in conjunction with investigators in the Children's Oncology Group, where I am specifically interested in studies of minimal residual disease, as detected by flow cytometry, and its effect on prognosis. I am also interested in developing new clinical applications of flow cytometry, particularly as it applies to blood and bone marrow.

Publications
Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL, Camitta B. (2003) Minimal residual disease detection in childhood precursor–B-cell acute lymphoblastic leukemia: Relation to other risk factors. A Children’s Oncology Group Study Leukemia 17:1566-1572

Weir EG, Cowan K, LeBeau P, Borowitz MJ. (1999) A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B-precursors with four color flow cytometry: implications for residual disease detection. Leukemia 13:558-567.

Nicol TL, Silberman M, Rosenthal DL, Borowitz MJ. (2000) The accuracy of combined cytopathologic and flow cytometric analysis of fine-needleaspirates of lymph nodes. Am J Clin Pathol; 114:18-28.

Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, Borowitz MJ. (2000) Improved detection and characterization of paroxysmalnocturnal hemoglobinuria using fluorescent aerolysin. AM J Clin Pathol 114:459-466.




Email kburns@jhmi.edu
Phone (410) 502-7214

Related Websites
Division of Hematologic Pathology

Burns Laboratory

Top of Page

Kathleen H. Burns, M.D., Ph.D.

Primary Appointment in Pathology; Secondary Appointment in Oncology
Member, Graduate Program in Pathobiology; Member, Institute of Genetic Medicine Predoctoral Training Program in Human Genetics
Affiliated faculty, High Throughput Biology Center


My laboratory studies roles of transposable elements in human cancers, with an emphasis on the hematopoietic neoplasias. There is compelling evidence that these poorly understood mobile DNAs have potential to contribute to genomic instability and mRNA transcript alterations in the context of neoplasia, and we believe inherited insertions also may create predispositions to disease.

Projects in the lab include: (i.) The development of one-sided PCR based assays to map transposon insertions in the human genome; (ii.) Finding evidence for somatic insertions of mobilized DNAs in cancers, and exploring potential clinical markers for this instability; (iii.) Describing common inherited transposon insertion polymorphisms in cancer patients and assessing whether these structural variations contribute to cancer susceptibility or tumor progression.

Publications

Huang CR, Burns KH, Boeke JD., Active transposition in genomes., Annu Rev Genet. 2012;46:651-75.

Burns KH, Boeke JD., Human transposon tectonics., Cell. 2012 May 11;149(4):740-52.

Huang CR, Schneider AM, Lu Y, Niranjan T, Shen P, Robinson MA, Steranka JP, Valle D, Civin CI, Wang T, Wheelan SJ, Ji H, Boeke JD, Burns KH., Mobile interspersed repeats are major structural variants in the human genome., Cell. 2010 Jun 25;141(7):1171-82.

Ma L, Buchold GM, Greenbaum MP, Roy A, Burns KH, Zhu H, Han DY, Harris RA, Coarfa C, Gunaratne PH, Yan W, Matzuk MM., GASZ is essential for male meiosis and suppression of retrotransposon expression in the male germline.PLoS Genet. 2009 Sep;5(9):e1000635

O'Donnell KA, Burns KH, Boeke JD., A descent into the nuage: the maelstrom of transposon control., Dev Cell. 2008 Aug;15(2):179-81.




Email aduffie1@jhmi.edu
Phone (410) 955-3580
Top of Page

Amy S. Duffield, M.D., Ph.D.

Assistant Professor of Pathology


Many patients with acute myeloid leukemia have tumor cells that express mutant FMS-Like tyrosine kinase 3 (FLT3). The mutant protein often carries activating mutations, and patients with these activating mutations have a particularly poor prognosis. FLT3 is a promising therapeutic target; however, FLT3 inhibitors have consistently shown disappointing results in clinical trials. I work with Donald Small's laboratory (Pediatric Oncology) to characterize novel FLT3 interactors in order to identify mechanisms that could enhance the efficacy of existing FLT3 inhibitors and uncover new drug targets.

Publications
http://www.ncbi.nlm.nih.gov/pubmed/?term=Duffield+A%2C+Hopkins



Email tkickler@jhmi.edu
Phone (410) 955-6315
Top of Page

Thomas S. Kickler, M.D.

Primary Appointment in Pathology;
Secondary Appointments in Medicine and Oncology


Dr. Kickler is the Director of Hematology and Coagulation Laboratories in the Department of Pathology.

He is also Co-Director of the Core Laboratory, in the Department of Pathology, and serves as Director of Phlebotomy Services, and as Physican Advisor for Pathology.

He is board certified in Internal Medicine and Hematology and Clinical Pathology.

Current research is in the role of platelet activation in coronary artery restenosis, and atherosclerosis in chronic cocaine use.

He is author of more than 150 peer reviewed publications.



Publications
Takemoto, C.M, Jani J, Streiff Mj, Chen J, Kickler, T. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol. 139:450-6, 2013.

Kakououse N, Kickler T, Rade J. J Thromb Haemost 11(10) 1814-22, 2013 . Hematocrit alters Verify P2Y12 assay results independently of intrinsic platelet reactivity and clopridogrel responsiveness.

DeFillipis AP, Oloyede OS, Guallar E, Blumenthal RS, Kickler TS, Rade JJ. Thromboxane generation in absence of Cox-1 activity in patients with myocardial infarction. Circulation 77(11) 2786-93, 2014.

Lai H, Stitzer M, Treisman G, Moore R, Brinker J, Gerstenblith G, Kickler TS, Li J, Chen S, Fishman E, Lai S. Cocaine abstinence and reduced use associated with lowered marker of endothelial dysfunction in African Americans, J Addict Med. 2015 Jul 7.

Streiff MB, Ye X, Kickler TS, Desideri S, Jani J, Fisher J, Grossman SA. A prospective multicenter study of venous thromboembolism in patietns with newly diagnosed high grade glioma, hazard rates and risk factors. J Neurooncol. 2015 Jun 23.

Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS Brodsky RA Modified Ham test for atypical hemolytic uremic syndrome. .Blood. 2015 Jun 4;125(23):3637-46.



 


Copyright © 2017 Johns Hopkins University. All Rights Reserved